Jeremy Barton
Profile
Jeremy Barton joined Seattle Genetics in November 2004.
In his role as Senior Medical Director, Dr. Barton is responsible for the clinical development activities of a number of the company's product candidates.
Prior to joining Seattle Genetics, he was a clinical development consultant to multiple biotechnology companies in the United Kingdom.
Previously, Dr. Barton was with Millennium Pharmaceuticals in London as Director of Clinical Research, Oncology, where he was involved in European drug development and commercialization activities.
Before that, he held senior clinical research positions at Elan Pharmaceuticals, Astra Zeneca and Glaxo Wellcome covering all phases of oncology drug development, working with cytotoxics, biologicals and signal transduction inhibitors.
Dr. Barton received his medical training at Oxford University and at University College Hospital Medical School in London.
His post graduate experience is in internal medicine and clinical oncology and he is board certified in medical oncology and radiation oncology.
Dr. Barton is a member of the Royal College of Physicians in the U.K.
and is a fellow of the Royal College of Radiologists
Former positions of Jeremy Barton
Companies | Position | End |
---|---|---|
SEAGEN INC. | Chief Tech/Sci/R&D Officer | - |
Experiences
Positions held
Linked companies
Private companies | 1 |
---|---|
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Jeremy Barton